Quotables
"There is practically no chance communications space satellites will be used to provide better telephone, telegraph, television, or radio service inside the United States."
T. Craven, FCC Commissioner ; 1961
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7605130 | Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed. ... | 10/20/2009 |
| 7605127 | Truncated hepatocyte growth factor variant protein HGF/NK2 The present invention relates to a novel truncated form of heptocyte growth factor (HGF) which specifically antagonizes the activity of HGF and to a novel truncated form of HGF that is a partial HGF agonist. In particular, the present invention relates to the purifi... | 10/20/2009 |
| 7605128 | Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia This invention pertains to the identification of neurogenerative and/or neurotrophic factors that can induce migration of stem cells to neural tissue and/or induce proliferation and/or differentiation of such cells into neurons. Such agents include, but are not limi... | 10/20/2009 |
| 7605129 | Splice variant of human placental growth hormone This invention relates to a protein, termed INSP105, herein identified as a splice variant of human placental growth hormone and to the use of this protein and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease. ... | 10/20/2009 |
| 7601691 | Anti-obesity agents The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The prese... | 10/13/2009 |
| 7601692 | MCP-1 splice variants and methods of using same Novel MCP-1 splice variant polypeptides and polynucleotides encoding same are provided. Also provided are pharmaceutical compositions comprising the splice variant polypeptides and polynucleotides, vectors and host cells comprising same. The compositions of the pres... | 10/13/2009 |
| 7601693 | Composition for treating cancer and use thereof The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer. | 10/13/2009 |
| 7598222 | Process for solubilizing glucagon-like peptide 1 compounds Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to for... | 10/06/2009 |
| 7595295 | Use of pleiotrophin to promote neurogeneration The invention provides methods for promoting neuron survival in patients by administering pleiotrophin, or nucleic acids encoding pleiotrophin. Uses of the invention include promoting neuron graft survival, preventing or reducing nervous system degeneration, and res... | 09/29/2009 |
| 7595296 | Mutant polypeptides of fibroblast growth factor 1 The β-trefoil protein human fibroblast growth factor-1 (FGF-1) is made up of a six-stranded anti-parallel β-barrel closed off on one end by three β-hairpins, thus exhibiting a three-fold axis of structural symmetry. The N- and C-termini β-strands hydrogen bond t... | 09/29/2009 |
| 7592314 | Use of VEGF and homologues to treat neuron disorders The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorde... | 09/22/2009 |
| 7592312 | Methods of modulating gastrointestinal contractility The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypep... | 09/22/2009 |
| 7592313 | Method of stimulating proliferation of regulatory T cells in a diabetic mammal The thymus-derived CD4+CD25+ T cells belong to a subset of regulatory T cells potentially capable of suppressing the proliferation of pathogenic effector T cells. Intriguingly, these suppressor cells are themselves anergic, proliferating poorly... | 09/22/2009 |
| 7592310 | Induction of antibiotic proteins and peptides by LAIT/sCD14-protein A method of ameliorating the symptoms of sepsis comprising directly exposing epithelial cells of a mammal in need thereof to soluble CD14, or active variants thereof. A method of obtaining CD14 from a stock solution containing protein of a mammary secretion is descr... | 09/22/2009 |
| 7592309 | Method of using a peptide having analgesic and antitumor activity from scorpion The present invention relates to a peptide having analgesic and antitumor activity derived from the scorpion and partial fragment, derivative or analogue thereof having analgesic and antitumor activity, and preparation method and use thereof. The peptide having anal... | 09/22/2009 |
| 7592311 | Platelet production promoting agent The invention relates to a polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino group in a polypeptide molecule having human granulocyte colony stimulating factor activity is chemically modified by a chemical modifying agent, and a platelet... | 09/22/2009 |
| 7585840 | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease The invention relates to the use of osteoprotegerin for treatment and/or prevention of fibrotic diseases, in particular of scleroderma. ... | 09/08/2009 |
| 7585841 | Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src The present invention describes methods for modulating angiogenesis in tissues using Src protein, modified Src protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Src protein, or nu... | 09/08/2009 |
| 7585842 | Human kunitz-type inhibitor with enhanced antifibrinolytic activity A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2). ... | 09/08/2009 |
| 7582606 | Nadph oxidase cytosolic cofactor mutant A purified polypeptide includes an NADPH oxidase cytosolic cofactor polypeptide NOXA1 or p67phox having a C-terminal SH3 domain insertion mutation of at least three consecutive amino acids positioned between PEDL (SEQ ID NO: 35) and GIFPK (SEQ ID NO: 34) ... | 09/01/2009 |
| 7582607 | Muteins of fibroblast growth factor 21 The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The ... | 09/01/2009 |
| 7582608 | Selective VPAC2 receptor peptide agonists The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. ... | 09/01/2009 |
| 7579315 | Casein peptides for alleviating or preventing aging of skin Provided is use of a peptide, or a derivative of a peptide, in the manufacture of a medicament effective in alleviating or preventing periodontal disease, wherein the peptide comprises an amino acid sequence present in an α-S2 casein precursor, said sequence compri... | 08/25/2009 |
| 7579316 | Compositions and methods to modulate an immune response to an immunogenic therapeutic agent Methods and compositions for modulating an immune response to an immunogenic therapeutic agent are disclosed. One of the disclosed methods comprises administering an effective amount of CTLA-4 to decrease the incidence of an immune reaction in conjunction with the a... | 08/25/2009 |
| 7579317 | Nutraceutical composition comprising soluble keratin or derivative thereof Keratin and derivatives thereof, preferably S-sulfonated keratin intermediate filament protein, S-sulfonated keratin high sulfur protein, and S-sulfonated peptides provide antioxidant activity, e.g., that equal to 200-2200 μmol TEAC/100 g or 100 ml, and are useful ... | 08/25/2009 |
| 7576058 | Method for importing biologically active molecules into cells The present invention relates to the delivery of biologically active molecules, such as peptides, nucleic acids and therapeutic agents, into the interior of cells by administering to the cells a complex comprising the molecule linked to an importation competent sign... | 08/18/2009 |
| 7576060 | Inhibition of adhesion and migration of an endothelial cell to fibronectin by neutrophil alpha-defensins The present invention relates to the inhibition of angiogenesis by neutrophil alpha-defensins. Further, the present invention relates to methods involving the inhibition of endothelial cell adhesion to the extracellular matrix, endothelial cell apoptosis, and endoth... | 08/18/2009 |
| 7576059 | Peptide derivatives A pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent pep... | 08/18/2009 |
| 7572772 | Soluble CTLA4 mutant molecules The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fus... | 08/11/2009 |
| 7572771 | Multi-domain amphipathic helical peptides and methods of their use Disclosed herein are peptides or peptide analogs with multiple amphipathic α-helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. Also provided herein are methods of using multi-domain amphipathic α-helical peptides or peptide analo... | 08/11/2009 |
| 7572770 | Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes Substances that inhibit the action of the members of the IL-1β/NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1... | 08/11/2009 |
| 7569545 | Methods of increasing neurotrophic factor expression Methods of treating brain tissue damage and increasing expression of a trophic factor in a cell. ... | 08/04/2009 |
| 7569543 | Compositions of Angiopoietin, fragments, mutants and analogs thereof and uses of the same The present invention relates to Ang-1, Ang-2, and Ang-3, and to methods and uses of the same. The present invention also relates to ECM-binding fragments, non-ECM-binding fragments, proteolytic resistant fragments and C-terminal fragments of Ang-1, and to methods a... | 08/04/2009 |
| 7569542 | Anti-microbial targeting chimeric pharmaceutical The present invention is based on the discovery of a composition that provides targeted anti-microbial effect. Specifically the composition contains a targeting moiety which recognizes a target microbial organism and an anti-microbial peptide moiety which has anti-m... | 08/04/2009 |
| 7569544 | Methods of increasing delivery of active agents to brain comprising administering receptor associated protein (RAP) fragments conjugated to active agents The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier. ... | 08/04/2009 |
| 7566696 | Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis Methods for treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally, 1,25-dihydroxyvitamin D analogs can be used in combination with the ca... | 07/28/2009 |
| 7566695 | Multimeric apoprotein agonists The present invention provides multimeric apoprotein agonists. Pharmaceutical compositions which include a multimeric apoprotein agonist and a pharmaceutically acceptable carrier, excipient or diluent are also provided. These pharmaceutical are useful to treat a var... | 07/28/2009 |
| 7563770 | Glucagon-like-peptide-2 (GLP-2) analogues GLP-2 analogues are disclosed which comprise one of more substitutions as compared to [hGly2]GLP-2 and which improved biological activity in vivo and/or improved chemical stability, e.g. as assessed in in vitro stability assays. More particularly, preferred GLP-2 an... | 07/21/2009 |
| 7563767 | Beta defensin proteins This invention relates to novel proteins, termed INSP 108 and INSP 109, herein identified as members of the defensin family of proteins and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of ... | 07/21/2009 |
| 7563766 | Methods and compositions for the promotion of a hair growth utilizing actin binding peptides Disclosed herein are methods and compositions suitable for the promotion of hair growth on humans and other animals. Disclosed embodiments include compositions comprising actin-binding peptides. In some embodiments, the actin-binding peptides comprise fragments of t... | 07/21/2009 |
